8-K filing — Evofem Biosciences, Inc. (EVFM)
Filed: 2026-09-23 AccNo: 0001493152-26-043919 Size: 578 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-23 AccNo: 0001493152-26-043919 Size: 578 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Wells Fargo analyst Stephen Tusa initiates coverage on Hubbell (NYSE:HUBB) with a Equal-Weight rating and announces Price Target of $531.
Hubbell, a grid-technology equipment manufacturer, has delivered 425% total returns over the past decade with ~18% annualized returns. The company is benefiting from surging electricity demand driven by data centers, AI, manufacturing, and electrification, which is fueling grid modernization investments. Q2 sales grew 15% organically, and management raised 2026 earnings guidance to $20.25-$20.55 per share. With a 130-year history and 18 consecutive years of dividend increases, Hubbell could offer long-term investors significant wealth-building potential if it maintains strong compounding growth.